📊 𝐈𝐍𝐕𝐄𝐒𝐓𝐎𝐑 𝐍𝐎𝐓𝐄: Drug Discovery Informatics Market Projected to Reach $7.74 Billion by 2030 as AI Agents Need Biological Context - $Microsoft(MSFT.US) $Palantir Tech(PLTR.US) $Snowflake(SNOW.US) $Veeva Systems -CL(VEEV.US) $MindWalk(HYFT.US)
Veeva Systems -CL
VEEV----
Veeva Systems -CL (VEEV)
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin A...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
- 52wk Low
- --
- Float Mkt Cap
- --
- Market Cap
- --
- P/ETTM
- --
- P/EDynamic
- --
- P/EStatic
- --
- EPSTTM
- --
- EPSDynamic
- --
- EPSStatic
- --
- BVPS
- --
- P/B
- --
- Circulating Supply
- --
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- --
- Min lot size
- --
- Currency
- --
Veeva Systems -CL Analyst Rating
View moreForecast & Rating
Oct 30, 2026Price forecast
$303.52-0.53%
Forecast & RatingBuy
29analysts
- Strong buy44.83%
- Buy24.14%
- Hold27.59%
- Sell3.45%
- Strong sell0.00%
Daily Events
- Jun, 4
Veeva's pre-market rally of 2.3% to $182.75 reversed sharply during regular trading, tumbling from an intraday high of $185.3 at market open (09:30 ET) to a close of $178.6, down 3.6%. The selloff came despite strong Q1 2027 results with revenue of $882.9M up 16.3% YoY and EPS up 14.6% to $1.57, plus unveiling of new Falcon and Agentic Biopharma products at Veeva Summit. The weakness reflects profit-taking momentum and divergent analyst sentiment on valuation. Target prices now vary widely: UBS cut guidance to $190, Barclays maintains $235, while Goldman Sachs issued a pessimistic outlook. The stock is down 18.6% YTD and off 42% from its October 2025 52-week high of $310.5, now trading below the 60-day moving average of $169.3.
News
- Weekly Review ·
Weekly Recap | Veeva Systems -CL +4.09%, most brokers rate it buy
- Weekly Review ·
Weekly Recap | Veeva Systems -CL +4.81%, IQVIA expands partnership
- Weekly Review ·
Weekly Recap | Veeva Systems -CL +8.34%, a late-week rally to the top of the range
- Weekly Review ·
Weekly Recap | VEEV.US -2.62%, most brokers rate it buy
- Weekly Review ·
Weekly Recap | Veeva Systems -CL +7.87%, Vault CRM wins another top biopharma
Posts
View more- M
Breaking: Michael Burry has disclosed his updated positions
He:• Trimmed Veeva $Veeva Systems -CL(VEEV.US) longs - 3% position• Trimmed PayPal $Paypal(PYPL.US) longs - 3% positionMichael Burry said "I will add [PYPL] should it fall to the mid $40s" - M
Breaking: Michael Burry has disclosed his updated positions
He:• Bought CoreWeave $Coreweave(CRWV.US) shorts• Added to Micron $Micron Tech(MU.US) shorts• Added to Palantir $Palantir Tech(PLTR.US) shorts• Added to Semiconductor ETF $SOXX shorts• Added to Mercado Libre $Mercadolibre(MELI.US) longs at $1890s• Added to Lululemon $Lululemon(LULU.US) longs at $115s• Added to Molina $Molina Healthcare(MOH.US) at $201• Bought Sprouts Farmer’s Markets $Sprouts Farmers(SFM.US) shares at $70s• Bought Temple & Webster $TPLWF shares in low $3s• Bought Build-a-Bear $Build A Bear(BBW.US) in mid-upper $30s• Trimmed PayPal $Paypal(PYPL.US)• Trimmed Veeva $Veeva Systems -CL(VEEV.US)Michael Burry said "The vast majority of people should never short, and likewise should never be on margin."